GORE TAG Thoracic Branch Endoprosthesis (TBE Device)
W. L. Gore & Associates, Inc. · Decision date Aug 21, 2025
What did the FDA approve?
FDA records P210032/S019 as a supplement to PMA P210032, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 21, 2025.
FDA approval order statement
approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P210032/S015.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 21, 2025
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P210032/S019
- Regulatory pathway
- PMA supplement
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- MIH
- Decision code
- APPR
- Decision date
- Aug 21, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT.
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- MIH
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P210032/S019 received
Application receipt date recorded by FDA.
P210032/S019 · FDA decision
Normal 180 Day Track No User Fee
P210032/S022 · Related supplement
TAG Thoracic Branch Endoprosthesis (P210032)
P210032/S023 · Related supplement
GORE TAG Thoracic Branch Endoprosthesis
P210032/S024 · Related supplement
GORE TAG Thoracic Branch Endoprosthesis
P210032/S025 · Related supplement
GORE TAG Conformable Thoracic Stent Graft with ACTIVE CONTROL System
P210032/S026 · Related supplement
GORE TAG Thoracic Branch Endoprosthesis Zone 0/1
Timeline entries are records held by MedtechLedger for P210032. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210032
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
TAG Thoracic Branch Endoprosthesis (P210032)P210032/S022 | W. L. Gore & Associates, Inc. | PMA supplement | Aug 25, 2025 | FDA |
GORE TAG Thoracic Branch EndoprosthesisP210032/S023 | W. L. Gore & Associates, Inc. | PMA supplement | Sep 9, 2025 | FDA |
GORE TAG Thoracic Branch EndoprosthesisP210032/S024 | W. L. Gore & Associates, Inc. | PMA supplement | Oct 17, 2025 | FDA |
| W. L. Gore & Associates, Inc. | PMA supplement | Mar 9, 2026 | FDA | |
GORE TAG Thoracic Branch Endoprosthesis Zone 0/1P210032/S026 | W. L. Gore & Associates, Inc. | PMA supplement | Jul 13, 2026 | FDA |
Explore the linked device profile
Other records with product code MIH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
RelayPro Thoracic Stent-Graft Delivery SystemP200045/S025 | Bolton Medical, Inc. | PMA supplement | Oct 28, 2026 | FDA |
| Cook, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Cook, Inc. | PMA supplement | Aug 4, 2026 | FDA | |
| Cook Medical Incorporated | PMA supplement | Aug 4, 2026 | FDA | |
| William Cook Europe Aps | PMA supplement | Aug 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
W. L. Gore & Associates, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3450 W. Kiltie Ln., Flagstaff, AZ, 86005
Sources and methodology
- Original FDA record: P210032/S019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





